Evidence map›Paper›PMID 32818204›Full record

ArticleThe Lancet. Rheumatology2020

Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach.

George A Robinson, Junjie Peng, Pierre Dönnes, Leda Coelewij, Meena Naja, Anna Radziszewska, Chris Wincup, Hannah Peckham, David A Isenberg, Yiannis Ioannou and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 81 citations in OpenAlex.

  1. Effects ofNarra J · 2024
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Lupus Nephritis Risk Factors and Biomarkers: An Update.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

George A RobinsonCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Junjie PengCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Pierre DönnesCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Leda CoelewijCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Meena NajaCentre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, UK.
Anna RadziszewskaCentre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, UK.
Chris WincupCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Hannah PeckhamCentre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, UK.
David A IsenbergCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Yiannis IoannouCentre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, UK.
Ines Pineda-TorraCentre for Cardiometabolic and Vascular Science, Department of Medicine, University College London, London, UK.
Coziana CiurtinCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
Elizabeth C JuryCentre for Rheumatology Research, Department of Medicine, University College London, London, UK.
University College London · GBVersus Arthritis · GBUCB Pharma (United Kingdom) · GB

Funding

Versus Arthritis 21992Versus Arthritis 22203
6 · The paper itself

Abstract

backgroundJuvenile-onset systemic lupus erythematosus (SLE) is a rare autoimmune rheumatic disease characterised by more severe disease manifestations, earlier damage accrual, and higher mortality than in adult-onset SLE. We aimed to use machine-learning approaches to characterise the immune cell profile of patients with juvenile-onset SLE and investigate links with the disease trajectory over time.

methodsThis study included patients who attended the University College London Hospital (London, UK) adolescent rheumatology service, had juvenile-onset SLE according to the 1997 American College of Rheumatology revised classification criteria for lupus or the 2012 Systemic Lupus International Collaborating Clinics criteria, and were diagnosed before 18 years of age. Blood donated by healthy age-matched and sex-matched volunteers who were taking part in educational events in the Centre for Adolescent Rheumatology Versus Arthritis at University College London (London, UK) was used as a control. Immunophenotyping profiles (28 immune cell subsets) of peripheral blood mononuclear cells from patients with juvenile-onset SLE and healthy controls were determined by flow cytometry. We used balanced random forest (BRF) and sparse partial least squares-discriminant analysis (sPLS-DA) to assess classification and parameter selection, and validation was by ten-fold cross-validation. We used logistic regression to test the association between immune phenotypes and k-means clustering to determine patient stratification. Retrospective longitudinal clinical data, including disease activity and medication, were related to the immunological features identified.

findingsBetween Sept 5, 2012, and March 7, 2018, peripheral blood was collected from 67 patients with juvenile-onset SLE and 39 healthy controls. The median age was 19 years (IQR 13-25) for patients with juvenile-onset SLE and 18 years (16-25) for healthy controls. The BRF model discriminated patients with juvenile-onset SLE from healthy controls with 90·9% prediction accuracy. The top-ranked immunological features from the BRF model were confirmed using sPLS-DA and logistic regression, and included total CD4, total CD8, CD8 effector memory, and CD8 naive T cells, Bm1, and unswitched memory B cells, total CD14 monocytes, and invariant natural killer T cells. Using these markers patients were clustered into four distinct groups. Notably, CD8 T-cell subsets were important in driving patient stratification, whereas B-cell markers were similarly expressed across the cohort of patients with juvenile-onset SLE. Patients with juvenile-onset SLE and elevated CD8 effector memory T-cell frequencies had more persistently active disease over time, as assessed by the SLE disease activity index 2000, and this was associated with increased treatment with mycophenolate mofetil and an increased prevalence of lupus nephritis. Finally, network analysis confirmed the strong association between immune phenotype and differential clinical features.

interpretationMachine-learning models can define potential disease-associated and patient-specific immune characteristics in rare disease patient populations. Immunological association studies are warranted to develop data-driven personalised medicine approaches for treatment of patients with juvenile-onset SLE.

fundingLupus UK, The Rosetrees Trust, Versus Arthritis, and UK National Institute for Health Research University College London Hospital Biomedical Research Centre.

Identifiers

PMID32818204
PMCPMC7425802
OpenAlexW3046387576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.